Clinical trials: BKV Infection
Infection
Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant
Patients enrolled on this study will have received a stem cell transplant. After a transplant, while the immune system grows back the patient is at risk for infection.
- Trial name
- CHARMS (NCT02108522)
- Testing
- Multivirus Specific T cells
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- AlloVir
BK Virus Infection, Hemorrhagic Cystitis
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC).
- Trial name
- NCT04390113
- Testing
- Posoleucel (ALVR105)
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 97 people
- Sponsor
- AlloVir
Adenovirus Infection, BK Virus Infection
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
This is a Phase 3 study to evaluate posoleucel (ALVR105, Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- Prevent (NCT05305040)
- Testing
- Posoleucel (ALVR105)
- Where
- 88 sites in United States, Australia and 8 more
- Volunteers
- 451 people
- Sponsor
- AlloVir
Viral Infection
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
The subjects eligible for this trial have a type of blood cell cancer, other blood disease or a genetic disease for which they will receive a stem cell transplant.
- Trial name
- ARMS (NCT01570283)
- Testing
- Multivirus-specific T cells Dose Level 1, Multivirus-specific T cells Dose Level 2, Multivirus-specific T cells Dose Level 3
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- AlloVir
Adenovirus Infection, BK Virus Infection
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
This is a Phase 2 study to evaluate posoleucel (ALVR105, formerly Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- Prevent (NCT04693637)
- Testing
- Posoleucel (ALVR105)
- Where
- 16 sites in United States
- Volunteers
- 26 people
- Sponsor
- AlloVir